---
title: "BHAS issued a profit warning, expecting a net profit attributable to shareholders of 270 million to 328 million yuan for the half-year, turning losses into profits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248406341.md"
description: "According to the Zhitong Finance APP, BHAS announced that the company expects to achieve a net profit attributable to shareholders of the listed company of between 270 million yuan and 328 million yuan for the first half of 2025, turning a profit compared to the same period last year"
datetime: "2025-07-14T11:03:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248406341.md)
  - [en](https://longbridge.com/en/news/248406341.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248406341.md)
---

# BHAS issued a profit warning, expecting a net profit attributable to shareholders of 270 million to 328 million yuan for the half-year, turning losses into profits

According to the Zhitong Finance APP, BHAS (600960.SH) announced that the company expects to achieve a net profit attributable to shareholders of the listed company of between 270 million yuan and 328 million yuan for the first half of 2025, turning a profit compared to the same period last year

### Related Stocks

- [600960.CN](https://longbridge.com/en/quote/600960.CN.md)

## Related News & Research

- [Is Kesko Oyj (HLSE:KESKOB) Undervalued Following Its Latest Sales Update?](https://longbridge.com/en/news/296027579.md)
- [Zijin Longking launches ZL230E 230-tonne battery-electric haul truck](https://longbridge.com/en/news/296209689.md)
- [Is HydroGraph Clean Power (CNSX:HG) Fully Valued Following Its Texas Expansion Plans?](https://longbridge.com/en/news/296027437.md)
- [Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study](https://longbridge.com/en/news/296068059.md)
- [DEVP_B: Q2 2026 saw a 30.9% sales drop, negative margins, and ongoing diversification beyond automotive](https://longbridge.com/en/news/296182978.md)